Details of the Drug Combinations

General Information of This Drug (ID: DMTA5OE)

Drug Name
Azacitidine   DMTA5OE
Synonyms
Azacitidina; Azacitidinum; Azacytidine; Ladakamycin; Mylosar; Vidaza; Mylo sar; Pharmion Brand of Azacitidine;A 2385; Antibiotic U 18496; U 18496; Wr 183027; Azacitidina [INN-Spanish]; Azacitidine [USAN:INN]; Azacitidinum [INN-Latin]; NS-17; Pyrimidine antimetabolite: inhibits nucleic acid replication; U-18496; Vidaz (TN); Vidaza (TN); WR-183027; Azacitidine (JAN/USAN/INN); S-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl-(8CI); 2-(beta-D-Ribofuranosyl)-4-amino-1,3,5-triazin-2-one; 4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-traizin-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazine-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one; 4-Amino-1-beta-d-ribofuranosyl-1,3,5-triazin-2(1H)-one; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triaz; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one; 4-amino-1-beta-L-ribofuranosyl-1,3,5-triazin-2(1H)-one; 5 AZC; 5 Azacytidine; 5-AC; 5-AZAC; 5-AZCR; 5-aza-CR; 5-azacitidine; 5-azacytidine; 5-azacytidine, Mylosar, Ladakamycin, Vidaza, Azacitidine; 5AzaC
Indication
Disease Entry ICD 11 Status REF
Acute myelogenous leukaemia 2A41 Approved [1]
Chronic myelomonocytic leukemia N.A. Approved [1]
Leukemia N.A. Approved [1]
Myelodysplastic syndrome 2A37 Approved [2]
Myeloproliferative neoplasm 2A20 Approved [1]
Plasma cell myeloma 2A83.1 Approved [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

408 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
10-hydroxycamptothecin + Azacitidine DCG46ZI 10-hydroxycamptothecin Adenocarcinoma (Cell Line: HCC-2998) [3]
10-hydroxycamptothecin + Azacitidine DCPZYHB 10-hydroxycamptothecin Large cell lung carcinoma (Cell Line: NCI-H460) [3]
10-hydroxycamptothecin + Azacitidine DCAVVER 10-hydroxycamptothecin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
ABIRATERONE + Azacitidine DCP72Y1 ABIRATERONE Anaplastic large cell lymphoma (Cell Line: SR) [4]
ABIRATERONE + Azacitidine DCNFJ7G ABIRATERONE Chronic myelogenous leukemia (Cell Line: K-562) [4]
ABIRATERONE + Azacitidine DCI1Z40 ABIRATERONE Glioblastoma (Cell Line: SNB-75) [4]
ABIRATERONE + Azacitidine DCHLSLV ABIRATERONE Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
ABIRATERONE + Azacitidine DC768PH ABIRATERONE Amelanotic melanoma (Cell Line: MDA-MB-435) [3]
ABIRATERONE + Azacitidine DC7029O ABIRATERONE Lung adenocarcinoma (Cell Line: EKVX) [3]
ABIRATERONE + Azacitidine DCXOVXN ABIRATERONE Malignant melanoma (Cell Line: LOX IMVI) [3]
Amonafide + Azacitidine DCTUJF0 Amonafide Adenocarcinoma (Cell Line: DU-145) [4]
Amonafide + Azacitidine DCPL0N2 Amonafide Astrocytoma (Cell Line: SNB-19) [4]
Amonafide + Azacitidine DC8SPL8 Amonafide Clear cell renal cell carcinoma (Cell Line: A498) [4]
Amonafide + Azacitidine DCRQNDO Amonafide High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Amonafide + Azacitidine DCQ56KW Amonafide Melanoma (Cell Line: SK-MEL-2) [4]
Amonafide + Azacitidine DCVK6SX Amonafide Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Amonafide + Azacitidine DCFSKTZ Amonafide Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Anastrozole + Azacitidine DCMNJEJ Anastrozole Adenocarcinoma (Cell Line: DU-145) [4]
Anastrozole + Azacitidine DC7RMWV Anastrozole Adenocarcinoma (Cell Line: A549) [4]
Anastrozole + Azacitidine DCZDQQB Anastrozole Adenocarcinoma (Cell Line: HCT-15) [4]
Anastrozole + Azacitidine DCLTZ89 Anastrozole Amelanotic melanoma (Cell Line: M14) [4]
Anastrozole + Azacitidine DCONU71 Anastrozole Clear cell renal cell carcinoma (Cell Line: A498) [4]
Anastrozole + Azacitidine DC7SQPL Anastrozole Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Anastrozole + Azacitidine DC5TPRB Anastrozole Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Anastrozole + Azacitidine DCA5N55 Anastrozole Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Anastrozole + Azacitidine DC75XKT Anastrozole Melanoma (Cell Line: MALME-3M) [4]
Anastrozole + Azacitidine DCWSKM9 Anastrozole Melanoma (Cell Line: SK-MEL-2) [4]
Anastrozole + Azacitidine DCY2VTA Anastrozole Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Anastrozole + Azacitidine DCQQGCV Anastrozole Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Anastrozole + Azacitidine DC1V1AW Anastrozole Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Anastrozole + Azacitidine DCHCHJK Anastrozole Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Anastrozole + Azacitidine DCEIOY4 Anastrozole Invasive ductal carcinoma (Cell Line: T-47D) [5]
Anastrozole + Azacitidine DC17HBZ Anastrozole Invasive ductal carcinoma (Cell Line: BT-549) [5]
Arfolitixorin + Azacitidine DCTZYAJ Arfolitixorin Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Azacitidine + Pentostatin DC3EGEU Pentostatin Anaplastic large cell lymphoma (Cell Line: SR) [4]
Azacitidine + Pentostatin DCV1KM4 Pentostatin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Azacitidine + Fulvestrant DCNPFQI Fulvestrant Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Azacitidine + Fulvestrant DC8LLJ4 Fulvestrant Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Azacitidine + Fulvestrant DC4XQJE Fulvestrant Chronic myelogenous leukemia (Cell Line: K-562) [4]
Azacitidine + Fulvestrant DC7SZK4 Fulvestrant Clear cell renal cell carcinoma (Cell Line: A498) [4]
Azacitidine + Fulvestrant DCWJMIL Fulvestrant Glioma (Cell Line: SF-268) [4]
Azacitidine + Fulvestrant DC8KWFL Fulvestrant High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Azacitidine + Fulvestrant DCGWSDO Fulvestrant Lung adenocarcinoma (Cell Line: HOP-62) [4]
Azacitidine + Fulvestrant DCI1T5H Fulvestrant Lung adenocarcinoma (Cell Line: EKVX) [4]
Azacitidine + Fulvestrant DCQVTYR Fulvestrant Melanoma (Cell Line: MALME-3M) [4]
Azacitidine + Fulvestrant DCX4CQA Fulvestrant Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Azacitidine + Fulvestrant DC3KQ0P Fulvestrant Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Azacitidine + Ruxolitinib DCO99M8 Ruxolitinib T-cell leukemia/lymphoma (Cell Line: ED-40515) [4]
Azacitidine + Ixabepilone DCHWGZH Ixabepilone Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Azacitidine + Ixabepilone DC0WR5E Ixabepilone Astrocytoma (Cell Line: SNB-19) [4]
Azacitidine + Ixabepilone DCHPJSA Ixabepilone Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Azacitidine + Ixabepilone DCD91GV Ixabepilone Lung adenocarcinoma (Cell Line: HOP-62) [4]
Azacitidine + Ixabepilone DC7SSOR Ixabepilone Malignant melanoma (Cell Line: UACC62) [4]
Azacitidine + Ixabepilone DC61H92 Ixabepilone Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Azacitidine + Dactinomycin DCJMHGD Dactinomycin Adenocarcinoma (Cell Line: HT29) [4]
Azacitidine + Dactinomycin DCIPPK2 Dactinomycin Adenocarcinoma (Cell Line: HCT116) [4]
Azacitidine + Dactinomycin DC9K9FH Dactinomycin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Azacitidine + Lapatinib DCGXNIU Lapatinib Anaplastic large cell lymphoma (Cell Line: SR) [4]
Azacitidine + Isoniazid DCNOSZ4 Isoniazid Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Azacitidine + Isoniazid DCGULA9 Isoniazid Lung adenocarcinoma (Cell Line: HOP-62) [4]
Azacitidine + Arsenic trioxide DC7F475 Arsenic trioxide Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Azacitidine + Plicamycin DCEAWJK Plicamycin Chronic myelogenous leukemia (Cell Line: K-562) [4]
Azacitidine + Triapine DCUP953 Triapine Lung adenocarcinoma (Cell Line: EKVX) [4]
Azacitidine + Topetecan DCXC8IA Topetecan Anaplastic large cell lymphoma (Cell Line: SR) [4]
Azacitidine + Pralatrexate DCWP73M Pralatrexate Adenocarcinoma (Cell Line: HCT116) [4]
Azacitidine + Pralatrexate DCJ1F0R Pralatrexate Astrocytoma (Cell Line: SNB-19) [4]
Azacitidine + Pralatrexate DCZYN8L Pralatrexate Chronic myelogenous leukemia (Cell Line: K-562) [4]
Azacitidine + Pralatrexate DCKXII4 Pralatrexate Glioma (Cell Line: SF-539) [4]
Azacitidine + Pralatrexate DCPHEJC Pralatrexate High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Azacitidine + Pralatrexate DCWJWBK Pralatrexate Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Azacitidine + Pralatrexate DC08S54 Pralatrexate Prostate carcinoma (Cell Line: PC-3) [4]
Azacitidine + Pralatrexate DC1HMSF Pralatrexate Renal cell carcinoma (Cell Line: UO-31) [4]
Azacitidine + Terameprocol DCAKDEC Terameprocol Adenocarcinoma (Cell Line: OVCAR3) [4]
Azacitidine + Terameprocol DCD7SX6 Terameprocol Adenocarcinoma (Cell Line: A549) [4]
Azacitidine + Terameprocol DCI9JEL Terameprocol Adenocarcinoma (Cell Line: HT29) [4]
Azacitidine + Terameprocol DCGJO6P Terameprocol Adenocarcinoma (Cell Line: HCT116) [4]
Azacitidine + Terameprocol DC9LU96 Terameprocol Adenocarcinoma (Cell Line: HCC-2998) [4]
Azacitidine + Terameprocol DCRLP89 Terameprocol Chronic myelogenous leukemia (Cell Line: K-562) [4]
Azacitidine + Terameprocol DCG8177 Terameprocol Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Azacitidine + Terameprocol DC4H9J4 Terameprocol Glioma (Cell Line: SF-539) [4]
Azacitidine + Terameprocol DCH5ARO Terameprocol High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Azacitidine + Terameprocol DCDGD21 Terameprocol Lung adenocarcinoma (Cell Line: EKVX) [4]
Azacitidine + Terameprocol DC1K6HM Terameprocol Lung adenocarcinoma (Cell Line: HOP-62) [4]
Azacitidine + Bendamustine hydrochloride DCVUTEC Bendamustine hydrochloride Adenocarcinoma (Cell Line: SW-620) [4]
Azacitidine + Bendamustine hydrochloride DC78Q5W Bendamustine hydrochloride Adenocarcinoma (Cell Line: HCT-15) [4]
Azacitidine + Bendamustine hydrochloride DCM4UM5 Bendamustine hydrochloride Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Azacitidine + Bendamustine hydrochloride DCA349R Bendamustine hydrochloride Anaplastic large cell lymphoma (Cell Line: SR) [4]
Azacitidine + Mitomycin DC8KAZM Mitomycin Adenocarcinoma (Cell Line: DU-145) [4]
Azacitidine + Mitomycin DCJ80N2 Mitomycin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Azacitidine + Mitomycin DCR7UTO Mitomycin Anaplastic large cell lymphoma (Cell Line: SR) [4]
Azacitidine + Mitomycin DCPC74T Mitomycin Astrocytoma (Cell Line: U251) [4]
Azacitidine + Mitomycin DCCJRMM Mitomycin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Azacitidine + Mitomycin DCOZHQR Mitomycin Chronic myelogenous leukemia (Cell Line: K-562) [4]
Azacitidine + Mitomycin DCA8V5I Mitomycin High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Azacitidine + Mitomycin DC1FRY6 Mitomycin Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Azacitidine + Mitomycin DCMH0UC Mitomycin Malignant melanoma (Cell Line: UACC62) [4]
Azacitidine + Mitomycin DCC9WWK Mitomycin Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Azacitidine + TEM DCKJ61H TEM Adenocarcinoma (Cell Line: NCIH23) [4]
Azacitidine + TEM DC4R34Z TEM Malignant melanoma (Cell Line: UACC62) [4]
Azacitidine + Bleomycin DC4PN3H Bleomycin Adenocarcinoma (Cell Line: HCT116) [4]
Azacitidine + Bleomycin DCE06QG Bleomycin Chronic myelogenous leukemia (Cell Line: K-562) [4]
Azacitidine + Valrubicin DCBDA4U Valrubicin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Azacitidine + Valrubicin DCEH6DW Valrubicin Glioblastoma (Cell Line: SNB-75) [4]
Azacitidine + Valrubicin DC600PR Valrubicin Lung adenocarcinoma (Cell Line: HOP-62) [4]
Azacitidine + Valrubicin DC67I93 Valrubicin Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Azacitidine + Cisplatin DC3479T Cisplatin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Azacitidine + Cisplatin DCF06YY Cisplatin Anaplastic large cell lymphoma (Cell Line: SR) [4]
Azacitidine + Cisplatin DCT6SNU Cisplatin Astrocytoma (Cell Line: U251) [4]
Azacitidine + Cisplatin DCOSOQJ Cisplatin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Azacitidine + Cisplatin DCCTTI5 Cisplatin Lung adenocarcinoma (Cell Line: EKVX) [4]
Azacitidine + Cisplatin DCFISDU Cisplatin Malignant melanoma (Cell Line: LOX IMVI) [4]
Azacitidine + Cisplatin DCU09N8 Cisplatin Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Azacitidine + Chlorambucil DCRAAM3 Chlorambucil Adenocarcinoma (Cell Line: NCIH23) [4]
Azacitidine + Chlorambucil DCA4UQX Chlorambucil Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Azacitidine + ER819762 DCPR94C ER819762 Adenocarcinoma (Cell Line: DU-145) [4]
Azacitidine + ER819762 DCJLJKU ER819762 Adenocarcinoma (Cell Line: OVCAR3) [4]
Azacitidine + ER819762 DCH89YW ER819762 Adenocarcinoma (Cell Line: A549) [4]
Azacitidine + ER819762 DCMO6FM ER819762 Adenocarcinoma (Cell Line: HCC-2998) [4]
Azacitidine + ER819762 DCKFP36 ER819762 Adenocarcinoma (Cell Line: HCT116) [4]
Azacitidine + ER819762 DCT73CK ER819762 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Azacitidine + ER819762 DCPA1IT ER819762 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Azacitidine + ER819762 DCI0BES ER819762 Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Azacitidine + ER819762 DC9TJK3 ER819762 Anaplastic large cell lymphoma (Cell Line: SR) [4]
Azacitidine + ER819762 DCTM26T ER819762 Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Azacitidine + ER819762 DCQJ3IK ER819762 Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Azacitidine + Vinflunine DCG68F4 Vinflunine Adenocarcinoma (Cell Line: HCT-15) [4]
Azacitidine + Vinflunine DCRV4OI Vinflunine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Azacitidine + Vinflunine DC46502 Vinflunine Astrocytoma (Cell Line: U251) [4]
Azacitidine + Vinflunine DCDA1JV Vinflunine Chronic myelogenous leukemia (Cell Line: K-562) [4]
Azacitidine + Vinflunine DCVL3D4 Vinflunine Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Azacitidine + Vinflunine DCHR2OQ Vinflunine Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Azacitidine + Vinflunine DCMD2S9 Vinflunine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Azacitidine + Vinflunine DCD4DBT Vinflunine High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Azacitidine + Vinflunine DCQOUAG Vinflunine Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Azacitidine + Mercaptopurine DCCPGG6 Mercaptopurine Adenocarcinoma (Cell Line: HT29) [4]
Azacitidine + Mercaptopurine DCZTD9P Mercaptopurine Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Azacitidine + Mercaptopurine DCAAA2G Mercaptopurine Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Azacitidine + Mercaptopurine DCJ4K0I Mercaptopurine Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Azacitidine + Mepacrine DCO44DS Mepacrine Anaplastic large cell lymphoma (Cell Line: SR) [4]
Azacitidine + Mepacrine DCH32D4 Mepacrine Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Azacitidine + Mepacrine DCCERSI Mepacrine High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Azacitidine + Mepacrine DC1UWNX Mepacrine Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Azacitidine + FORMESTANE DCKAVXG FORMESTANE Adenocarcinoma (Cell Line: NCIH23) [4]
Azacitidine + FORMESTANE DCKCJTM FORMESTANE Adenocarcinoma (Cell Line: HCT-15) [4]
Azacitidine + FORMESTANE DCKZFF0 FORMESTANE Adenocarcinoma (Cell Line: HCT116) [4]
Azacitidine + FORMESTANE DCQFV5F FORMESTANE Adenocarcinoma (Cell Line: HCC-2998) [4]
Azacitidine + FORMESTANE DC69HQY FORMESTANE Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Azacitidine + FORMESTANE DCB89NI FORMESTANE Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Azacitidine + FORMESTANE DC7ZP3L FORMESTANE Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Azacitidine + FORMESTANE DCUXONY FORMESTANE Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Azacitidine + FORMESTANE DCRD9EN FORMESTANE Melanoma (Cell Line: UACC-257) [4]
Azacitidine + Aminolevulinic Acid Hydrochloride DCNEY8L Aminolevulinic Acid Hydrochloride Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Azacitidine + Aminolevulinic Acid Hydrochloride DCYIWI1 Aminolevulinic Acid Hydrochloride Anaplastic large cell lymphoma (Cell Line: SR) [4]
Azacitidine + Aminolevulinic Acid Hydrochloride DCQDH35 Aminolevulinic Acid Hydrochloride Astrocytoma (Cell Line: U251) [4]
Azacitidine + Aminolevulinic Acid Hydrochloride DCRPCBI Aminolevulinic Acid Hydrochloride Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Azacitidine + Aminolevulinic Acid Hydrochloride DCDHFSK Aminolevulinic Acid Hydrochloride Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Azacitidine + Aminolevulinic Acid Hydrochloride DCJDJZL Aminolevulinic Acid Hydrochloride Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Azacitidine + Busulfan DCHMLIW Busulfan Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Azacitidine + Ibrutinib DCBJT6J Ibrutinib Diffuse large B cell lymphoma (Cell Line: TMD8) [4]
Azacitidine + Dasatinib DC5WFJK Dasatinib Anaplastic large cell lymphoma (Cell Line: SR) [4]
Azacitidine + Pentostatin DC5WFM7 Pentostatin Colon adenocarcinoma (Cell Line: COLO 205) [5]
Azacitidine + Ixabepilone DC2AO8O Ixabepilone Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Azacitidine + Terameprocol DCT5P2F Terameprocol Carcinoma (Cell Line: MCF7) [5]
Azacitidine + Mitomycin DC2VG9L Mitomycin Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Azacitidine + Mitomycin DCA90KE Mitomycin Invasive ductal carcinoma (Cell Line: BT-549) [5]
Azacitidine + Cisplatin DCSB7OF Cisplatin Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Azacitidine + Chlorambucil DCXEP0F Chlorambucil Carcinoma (Cell Line: RXF 393) [5]
Azacitidine + ER819762 DCB0MEU ER819762 Colon adenocarcinoma (Cell Line: COLO 205) [5]
Azacitidine + ER819762 DCJV4MR ER819762 Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Azacitidine + Vinflunine DC7F132 Vinflunine Colon carcinoma (Cell Line: KM12) [5]
Azacitidine + Vinflunine DC2RXT1 Vinflunine Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Azacitidine + Mepacrine DCLLHIS Mepacrine Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Azacitidine + FORMESTANE DC5XR27 FORMESTANE Colon adenocarcinoma (Cell Line: COLO 205) [5]
Azacitidine + FORMESTANE DCVLUDK FORMESTANE Invasive ductal carcinoma (Cell Line: T-47D) [5]
Azacitidine + Busulfan DCBTNRT Busulfan Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
BIO-300 + Azacitidine DCKN854 BIO-300 Astrocytoma (Cell Line: SNB-19) [4]
BIO-300 + Azacitidine DCYU5IP BIO-300 Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
BIO-300 + Azacitidine DC891XI BIO-300 Clear cell renal cell carcinoma (Cell Line: A498) [4]
BIO-300 + Azacitidine DCXYOWX BIO-300 Papillary renal cell carcinoma (Cell Line: ACHN) [4]
BIO-300 + Azacitidine DCLRY2X BIO-300 Adenocarcinoma (Cell Line: HT29) [3]
BIO-300 + Azacitidine DC3ZGZ4 BIO-300 High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [3]
BIO-300 + Azacitidine DCT4NGN BIO-300 Malignant melanoma (Cell Line: UACC62) [3]
BIO-300 + Azacitidine DC8BIDD BIO-300 Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Bleomycin + Azacitidine DCQHN6W Bleomycin Astrocytoma (Cell Line: SNB-19) [4]
Bleomycin + Azacitidine DCVOWR8 Bleomycin Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Bleomycin + Azacitidine DCTMFIG Bleomycin Invasive ductal carcinoma (Cell Line: BT-549) [5]
Bleomycin + Azacitidine DCMR0IG Bleomycin Adenocarcinoma (Cell Line: SW-620) [3]
Bleomycin + Azacitidine DC4FQIO Bleomycin Amelanotic melanoma (Cell Line: MDA-MB-435) [3]
Bleomycin + Azacitidine DCCV0E6 Bleomycin Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Bleomycin + Azacitidine DCOGUXL Bleomycin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Bleomycin + Azacitidine DCFZB2W Bleomycin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [3]
Cabazitaxel + Azacitidine DC63DU3 Cabazitaxel Adenocarcinoma (Cell Line: DU-145) [4]
Cabazitaxel + Azacitidine DCFHJ83 Cabazitaxel Adenocarcinoma (Cell Line: OVCAR3) [4]
Cabazitaxel + Azacitidine DCCFR9O Cabazitaxel Adenocarcinoma (Cell Line: HCC-2998) [4]
Cabazitaxel + Azacitidine DCUGLYX Cabazitaxel Adenocarcinoma (Cell Line: HCT-15) [4]
Cabazitaxel + Azacitidine DCERVDY Cabazitaxel Adenocarcinoma (Cell Line: HCT116) [4]
Cabazitaxel + Azacitidine DCY5III Cabazitaxel Adenocarcinoma (Cell Line: HT29) [4]
Cabazitaxel + Azacitidine DCIIW1V Cabazitaxel Anaplastic large cell lymphoma (Cell Line: SR) [4]
Cabazitaxel + Azacitidine DCGUSQ0 Cabazitaxel Astrocytoma (Cell Line: U251) [4]
Cabazitaxel + Azacitidine DC8605A Cabazitaxel Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Cabazitaxel + Azacitidine DCKMR3Y Cabazitaxel Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Cabazitaxel + Azacitidine DCOOVPT Cabazitaxel Clear cell renal cell carcinoma (Cell Line: A498) [4]
Cabazitaxel + Azacitidine DCQPUEH Cabazitaxel Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Cabazitaxel + Azacitidine DCGI3EN Cabazitaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
Cabazitaxel + Azacitidine DCHCJ6A Cabazitaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Cabazitaxel + Azacitidine DCREI8R Cabazitaxel Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Cabazitaxel + Azacitidine DCQ32W6 Cabazitaxel Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Cabazitaxel + Azacitidine DCOT0GT Cabazitaxel Lung adenocarcinoma (Cell Line: NCI-H522) [4]
Cabazitaxel + Azacitidine DCMH380 Cabazitaxel Malignant melanoma (Cell Line: UACC62) [4]
Cabazitaxel + Azacitidine DCDWZ2M Cabazitaxel Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Cabazitaxel + Azacitidine DCT49HG Cabazitaxel Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Cabazitaxel + Azacitidine DCOBJTF Cabazitaxel Prostate carcinoma (Cell Line: PC-3) [4]
Cabazitaxel + Azacitidine DCCKODX Cabazitaxel Renal cell carcinoma (Cell Line: SN12C) [4]
Cabazitaxel + Azacitidine DC7UAJB Cabazitaxel Renal cell carcinoma (Cell Line: UO-31) [4]
Cabazitaxel + Azacitidine DC4F5N6 Cabazitaxel Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Cabazitaxel + Azacitidine DC8NF0S Cabazitaxel Carcinoma (Cell Line: RXF 393) [5]
Cabazitaxel + Azacitidine DC783TC Cabazitaxel Carcinoma (Cell Line: MCF7) [5]
Cabazitaxel + Azacitidine DCT983B Cabazitaxel Invasive ductal carcinoma (Cell Line: BT-549) [5]
Crizotinib + Azacitidine DCUMX1B Crizotinib Anaplastic large cell lymphoma (Cell Line: SR) [4]
Crizotinib + Azacitidine DCXUT6W Crizotinib Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Crizotinib + Azacitidine DCXPVDA Crizotinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Crizotinib + Azacitidine DCK2DQD Crizotinib Invasive ductal carcinoma (Cell Line: T-47D) [5]
Dacarbazine + Azacitidine DCF4233 Dacarbazine Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Dacarbazine + Azacitidine DCU2T7P Dacarbazine Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Dacarbazine + Azacitidine DCEJIRJ Dacarbazine Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Dacarbazine + Azacitidine DCJBE8O Dacarbazine Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Dactinomycin + Azacitidine DC2A9AN Dactinomycin Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Dactinomycin + Azacitidine DCQQ03P Dactinomycin Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Dactinomycin + Azacitidine DC7LK1H Dactinomycin Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Dexrazoxane + Azacitidine DCH9MEI Dexrazoxane Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Dexrazoxane + Azacitidine DCS7L67 Dexrazoxane Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Dexrazoxane + Azacitidine DCLAEJ3 Dexrazoxane Adenocarcinoma (Cell Line: SW-620) [3]
Dexrazoxane + Azacitidine DC00T5O Dexrazoxane Amelanotic melanoma (Cell Line: MDA-MB-435) [3]
Dexrazoxane + Azacitidine DCVCKWF Dexrazoxane Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Dexrazoxane + Azacitidine DCOHOSB Dexrazoxane Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
DFN-15 + Azacitidine DC4N4OR DFN-15 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
DFN-15 + Azacitidine DCQ1NKA DFN-15 Colon carcinoma (Cell Line: KM12) [5]
DFN-15 + Azacitidine DCBN8A7 DFN-15 Invasive ductal carcinoma (Cell Line: T-47D) [5]
DFN-15 + Azacitidine DCV0X9T DFN-15 Adenocarcinoma (Cell Line: OVCAR3) [3]
DFN-15 + Azacitidine DCVTEHB DFN-15 Adenocarcinoma (Cell Line: HT29) [3]
DFN-15 + Azacitidine DCINM0I DFN-15 High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [3]
DFN-15 + Azacitidine DCDFCE4 DFN-15 Lung adenocarcinoma (Cell Line: EKVX) [3]
Digitoxin + Azacitidine DC225IB Digitoxin Adenocarcinoma (Cell Line: HT29) [4]
Digitoxin + Azacitidine DCSK9VL Digitoxin Malignant melanoma (Cell Line: UACC62) [4]
Docetaxel + Azacitidine DC396D9 Docetaxel Adenocarcinoma (Cell Line: HT29) [4]
Docetaxel + Azacitidine DCT6OHD Docetaxel Adenocarcinoma (Cell Line: HCC-2998) [4]
Docetaxel + Azacitidine DC8U7BJ Docetaxel Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Docetaxel + Azacitidine DC1J5FI Docetaxel Anaplastic large cell lymphoma (Cell Line: SR) [4]
Docetaxel + Azacitidine DCGJQ6F Docetaxel High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Docetaxel + Azacitidine DCLRHKH Docetaxel Malignant melanoma (Cell Line: UACC62) [4]
Docetaxel + Azacitidine DCYIUHE Docetaxel Colon adenocarcinoma (Cell Line: COLO 205) [5]
Epirubicin + Azacitidine DCKZDSG Epirubicin Glioblastoma (Cell Line: SNB-75) [4]
Epirubicin + Azacitidine DCC1U8B Epirubicin Colon carcinoma (Cell Line: KM12) [5]
Epirubicin + Azacitidine DC5VT37 Epirubicin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Estramustine + Azacitidine DC3VT2N Estramustine Adenocarcinoma (Cell Line: HT29) [3]
Estramustine + Azacitidine DCNC6I0 Estramustine Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Fludarabine + Azacitidine DCTLJ4B Fludarabine Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Fludarabine + Azacitidine DCFK4BU Fludarabine Large cell lung carcinoma (Cell Line: NCI-H460) [3]
FORMESTANE + Azacitidine DCZ7Y2O FORMESTANE Adenocarcinoma (Cell Line: HT29) [4]
Gefitinib + Azacitidine DCI72KH Gefitinib Adenocarcinoma (Cell Line: DU-145) [4]
Gefitinib + Azacitidine DCVOEDM Gefitinib Adenocarcinoma (Cell Line: A549) [4]
Gefitinib + Azacitidine DC1I4T3 Gefitinib Anaplastic large cell lymphoma (Cell Line: SR) [4]
Gefitinib + Azacitidine DCUJLM2 Gefitinib Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Gefitinib + Azacitidine DCI0KUK Gefitinib Melanoma (Cell Line: MALME-3M) [4]
Gefitinib + Azacitidine DCBRMR0 Gefitinib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Gefitinib + Azacitidine DC98NHM Gefitinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Gefitinib + Azacitidine DCTDIUD Gefitinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Gefitinib + Azacitidine DC83XIY Gefitinib Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Gefitinib + Azacitidine DCAMQ24 Gefitinib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Hepzato + Azacitidine DCGSUQK Hepzato Adenocarcinoma (Cell Line: HCC-2998) [3]
Indazole derivative 5 + Azacitidine DC9XHDF Indazole derivative 5 Anaplastic large cell lymphoma (Cell Line: SR) [4]
Indazole derivative 5 + Azacitidine DCGMAJD Indazole derivative 5 Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Indazole derivative 5 + Azacitidine DCKQ4GS Indazole derivative 5 Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Indazole derivative 5 + Azacitidine DCAPNDI Indazole derivative 5 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
JNK-IN-8 + Azacitidine DCQYBBO JNK-IN-8 Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
JNK-IN-8 + Azacitidine DC7E6R9 JNK-IN-8 Plasma cell myeloma (Cell Line: RPMI-8226) [4]
JNK-IN-8 + Azacitidine DCFTI2D JNK-IN-8 Large cell lung carcinoma (Cell Line: NCI-H460) [3]
JNK-IN-8 + Azacitidine DCWUT0I JNK-IN-8 Malignant melanoma (Cell Line: UACC62) [3]
Lenalidomide + Azacitidine DC890UZ Lenalidomide Glioblastoma (Cell Line: SNB-75) [4]
Lenalidomide + Azacitidine DCENO3T Lenalidomide Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Lenalidomide + Azacitidine DCG9D4Q Lenalidomide Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Lenalidomide + Azacitidine DCMVDSN Lenalidomide Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Lenalidomide + Azacitidine DCN7M9I Lenalidomide Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Lenalidomide + Azacitidine DC8EK6C Lenalidomide Melanoma (Cell Line: MALME-3M) [3]
Letrozole + Azacitidine DCZI38G Letrozole Adenocarcinoma (Cell Line: OVCAR3) [4]
Letrozole + Azacitidine DC0AHZ4 Letrozole Adenocarcinoma (Cell Line: NCIH23) [4]
Letrozole + Azacitidine DC6VX9J Letrozole Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Letrozole + Azacitidine DC5DSLM Letrozole Anaplastic large cell lymphoma (Cell Line: SR) [4]
Letrozole + Azacitidine DC4FCQ0 Letrozole Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Letrozole + Azacitidine DC487P2 Letrozole Glioma (Cell Line: SF-539) [4]
Letrozole + Azacitidine DC859JD Letrozole High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Letrozole + Azacitidine DCXPA4F Letrozole High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Letrozole + Azacitidine DCG1EUV Letrozole Malignant melanoma (Cell Line: LOX IMVI) [4]
Letrozole + Azacitidine DC6L1D2 Letrozole Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Letrozole + Azacitidine DC1V72L Letrozole Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Letrozole + Azacitidine DC73VSJ Letrozole Renal cell carcinoma (Cell Line: SN12C) [4]
Letrozole + Azacitidine DCVBH5F Letrozole Colon carcinoma (Cell Line: KM12) [5]
LIAROZOLE + Azacitidine DCRDRKB LIAROZOLE Adenocarcinoma (Cell Line: HT29) [3]
LIAROZOLE + Azacitidine DCJ936F LIAROZOLE Large cell lung carcinoma (Cell Line: NCI-H460) [3]
LIAROZOLE + Azacitidine DC54W9H LIAROZOLE Malignant melanoma (Cell Line: UACC62) [3]
Mechlorethamine + Azacitidine DC7F3JJ Mechlorethamine Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Mechlorethamine + Azacitidine DCGTR1C Mechlorethamine Amelanotic melanoma (Cell Line: MDA-MB-435) [3]
Mechlorethamine + Azacitidine DCGVCLQ Mechlorethamine Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Mechlorethamine + Azacitidine DCVQDMG Mechlorethamine Malignant melanoma (Cell Line: UACC62) [3]
Picoplatin + Azacitidine DCU0F3W Picoplatin Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Picoplatin + Azacitidine DCF432A Picoplatin Malignant melanoma (Cell Line: UACC62) [3]
Raloxifene + Azacitidine DCJMF9T Raloxifene Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Raloxifene + Azacitidine DCBSCRL Raloxifene Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Raloxifene + Azacitidine DCRKKJD Raloxifene Renal cell carcinoma (Cell Line: SN12C) [4]
Raloxifene + Azacitidine DCVW4AA Raloxifene Colon carcinoma (Cell Line: KM12) [5]
Raloxifene + Azacitidine DCE7H8N Raloxifene Adenocarcinoma (Cell Line: NCIH23) [3]
Raloxifene + Azacitidine DCD0HY4 Raloxifene Amelanotic melanoma (Cell Line: M14) [3]
Raloxifene + Azacitidine DCM4GST Raloxifene High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Raloxifene + Azacitidine DCT69HE Raloxifene Lung adenocarcinoma (Cell Line: EKVX) [3]
Raloxifene + Azacitidine DCLXZZV Raloxifene Melanoma (Cell Line: MALME-3M) [3]
Romidepsin + Azacitidine DCNK7V3 Romidepsin Glioma (Cell Line: SF-295) [4]
Romidepsin + Azacitidine DCNIJZQ Romidepsin Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Romidepsin + Azacitidine DCECOP7 Romidepsin Carcinoma (Cell Line: RXF 393) [5]
Romidepsin + Azacitidine DC9DK6H Romidepsin Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Romidepsin + Azacitidine DCTG5LS Romidepsin Malignant melanoma (Cell Line: UACC62) [3]
Ruxolitinib + Azacitidine DCY451E Ruxolitinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Ruxolitinib + Azacitidine DC25N58 Ruxolitinib Clear cell renal cell carcinoma (Cell Line: A498) [4]
Ruxolitinib + Azacitidine DCUQ9XJ Ruxolitinib Invasive ductal carcinoma (Cell Line: T-47D) [5]
Ruxolitinib + Azacitidine DCEIUIT Ruxolitinib Amelanotic melanoma (Cell Line: MDA-MB-435) [3]
Sirolimus + Azacitidine DCZAVVA Sirolimus Anaplastic large cell lymphoma (Cell Line: SR) [4]
Sirolimus + Azacitidine DC85V20 Sirolimus Chronic myelogenous leukemia (Cell Line: K-562) [4]
Sirolimus + Azacitidine DCOG0CU Sirolimus Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Sirolimus + Azacitidine DC4SD6F Sirolimus Colon carcinoma (Cell Line: KM12) [5]
Sirolimus + Azacitidine DCFOPTM Sirolimus Adenocarcinoma (Cell Line: DU-145) [3]
SY-1425 + Azacitidine DCUO7VZ SY-1425 Adenocarcinoma (Cell Line: HT29) [3]
Thioguanine + Azacitidine DCGN2H9 Thioguanine Anaplastic large cell lymphoma (Cell Line: SR) [4]
Thioguanine + Azacitidine DC04BJA Thioguanine Glioblastoma (Cell Line: SNB-75) [4]
Thioguanine + Azacitidine DCSFO93 Thioguanine Glioma (Cell Line: SF-295) [4]
Thioguanine + Azacitidine DC1ALVA Thioguanine Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Thioguanine + Azacitidine DCJ7TST Thioguanine Invasive ductal carcinoma (Cell Line: BT-549) [5]
Thioguanine + Azacitidine DCCQ67S Thioguanine Adenocarcinoma (Cell Line: SW-620) [3]
Thioguanine + Azacitidine DCPFTJX Thioguanine Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Thioguanine + Azacitidine DCULFFL Thioguanine Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Topotecan + Azacitidine DC6NEVT Topotecan Carcinoma (Cell Line: MCF7) [5]
Topotecan + Azacitidine DCY4PJT Topotecan Adenocarcinoma (Cell Line: SW-620) [3]
Topotecan + Azacitidine DCXTSI9 Topotecan Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Topotecan + Azacitidine DCGKR0K Topotecan Amelanotic melanoma (Cell Line: MDA-MB-435) [3]
Topotecan + Azacitidine DC5MLQ6 Topotecan Amelanotic melanoma (Cell Line: M14) [3]
Topotecan + Azacitidine DC9U3DI Topotecan Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Topotecan + Azacitidine DCD3AFH Topotecan Glioma (Cell Line: SF-268) [3]
Topotecan + Azacitidine DCZKPJS Topotecan Melanoma (Cell Line: MALME-3M) [3]
Topotecan + Azacitidine DCBKSJZ Topotecan Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Topotecan + Azacitidine DC4ADYF Topotecan Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Topotecan + Azacitidine DCDLA69 Topotecan Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Topotecan + Azacitidine DCY63GW Topotecan Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Topotecan + Azacitidine DC7U3BL Topotecan Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [3]
Trifluridine + Azacitidine DCTB1ZI Trifluridine Anaplastic large cell lymphoma (Cell Line: SR) [4]
Trifluridine + Azacitidine DC3HP20 Trifluridine Astrocytoma (Cell Line: U251) [4]
Trifluridine + Azacitidine DCJ3FUC Trifluridine Astrocytoma (Cell Line: SNB-19) [4]
Trifluridine + Azacitidine DCHEQNK Trifluridine Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Trifluridine + Azacitidine DCISMCW Trifluridine Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Trifluridine + Azacitidine DCGK85U Trifluridine Adenocarcinoma (Cell Line: OVCAR3) [3]
Trifluridine + Azacitidine DC24YO8 Trifluridine Adenocarcinoma (Cell Line: NCIH23) [3]
Trifluridine + Azacitidine DCUZG5I Trifluridine Adenocarcinoma (Cell Line: HT29) [3]
Trifluridine + Azacitidine DC6D3FC Trifluridine Lung adenocarcinoma (Cell Line: EKVX) [3]
Trifluridine + Azacitidine DCPICLB Trifluridine Prostate carcinoma (Cell Line: PC-3) [3]
Valrubicin + Azacitidine DCLSDBU Valrubicin Astrocytoma (Cell Line: U251) [4]
Valrubicin + Azacitidine DCBECHH Valrubicin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Valrubicin + Azacitidine DCAQJI9 Valrubicin Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Valrubicin + Azacitidine DCH906O Valrubicin Carcinoma (Cell Line: MCF7) [5]
Valrubicin + Azacitidine DCNO3M0 Valrubicin Invasive ductal carcinoma (Cell Line: T-47D) [5]
Valrubicin + Azacitidine DCNF2OB Valrubicin Adenocarcinoma (Cell Line: NCIH23) [3]
Valrubicin + Azacitidine DC04PYA Valrubicin Adenocarcinoma (Cell Line: HT29) [3]
Valrubicin + Azacitidine DCSBY8V Valrubicin Adenocarcinoma (Cell Line: HCT116) [3]
Valrubicin + Azacitidine DC3VVEO Valrubicin Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Valrubicin + Azacitidine DCFEXWJ Valrubicin Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Valrubicin + Azacitidine DCLULQ6 Valrubicin Lung adenocarcinoma (Cell Line: EKVX) [3]
Valrubicin + Azacitidine DCLMZR1 Valrubicin Malignant melanoma (Cell Line: UACC62) [3]
Valrubicin + Azacitidine DCD9LAI Valrubicin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Valrubicin + Azacitidine DCXL2RZ Valrubicin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Valrubicin + Azacitidine DCEQUQ8 Valrubicin Prostate carcinoma (Cell Line: PC-3) [3]
Vandetanib + Azacitidine DCS4QJT Vandetanib Colon carcinoma (Cell Line: KM12) [5]
Vandetanib + Azacitidine DCFU5G8 Vandetanib Invasive ductal carcinoma (Cell Line: T-47D) [5]
Vandetanib + Azacitidine DCQ4QTI Vandetanib Adenocarcinoma (Cell Line: NCIH23) [3]
Vandetanib + Azacitidine DC71CMP Vandetanib Amelanotic melanoma (Cell Line: MDA-MB-435) [3]
Vandetanib + Azacitidine DCPJN6G Vandetanib Chronic myelogenous leukemia (Cell Line: K-562) [3]
Vandetanib + Azacitidine DCALBWU Vandetanib Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Vandetanib + Azacitidine DCKLVO3 Vandetanib Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Vandetanib + Azacitidine DCS4EH7 Vandetanib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Vandetanib + Azacitidine DCPY3TK Vandetanib Non-small cell lung carcinoma (Cell Line: HOP-92) [3]
Vemurafenib + Azacitidine DC9L0UQ Vemurafenib Colon carcinoma (Cell Line: KM12) [5]
Vemurafenib + Azacitidine DCN84QZ Vemurafenib Invasive ductal carcinoma (Cell Line: T-47D) [5]
Vemurafenib + Azacitidine DCF9F90 Vemurafenib Adenocarcinoma (Cell Line: HT29) [3]
Vemurafenib + Azacitidine DCZIW8I Vemurafenib Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Vemurafenib + Azacitidine DC7UIIZ Vemurafenib Lung adenocarcinoma (Cell Line: EKVX) [3]
Vemurafenib + Azacitidine DC8NA4Y Vemurafenib Non-small cell lung carcinoma (Cell Line: HOP-92) [3]
Vemurafenib + Azacitidine DCW1SDN Vemurafenib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Vemurafenib + Azacitidine DC6DU99 Vemurafenib Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Vincristine + Azacitidine DC9ZNKG Vincristine Glioma (Cell Line: SF-268) [4]
Vincristine + Azacitidine DC5EVUQ Vincristine Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Vincristine + Azacitidine DCSBI2I Vincristine Malignant melanoma (Cell Line: UACC62) [4]
Vinflunine + Azacitidine DCW266T Vinflunine Colon adenocarcinoma (Cell Line: COLO 205) [5]
Vinflunine + Azacitidine DCNH903 Vinflunine Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Vinflunine + Azacitidine DC98UEQ Vinflunine Adenocarcinoma (Cell Line: HT29) [3]
Vinflunine + Azacitidine DC471QY Vinflunine Lung adenocarcinoma (Cell Line: MDA-MB-231) [3]
Vinflunine + Azacitidine DCI85AQ Vinflunine Malignant melanoma (Cell Line: UACC62) [3]
Vinflunine + Azacitidine DCIMY4C Vinflunine Melanoma (Cell Line: MALME-3M) [3]
Vismodegib + Azacitidine DCOF53Q Vismodegib Anaplastic large cell lymphoma (Cell Line: SR) [3]
Vismodegib + Azacitidine DCSGMC4 Vismodegib Chronic myelogenous leukemia (Cell Line: K-562) [3]
Vismodegib + Azacitidine DCUY268 Vismodegib Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Vismodegib + Azacitidine DC97HS8 Vismodegib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Vismodegib + Azacitidine DCYTFFQ Vismodegib Melanoma (Cell Line: UACC-257) [3]
Vismodegib + Azacitidine DCWF3NV Vismodegib Melanoma (Cell Line: MALME-3M) [3]
------------------------------------------------------------------------------------
⏷ Show the Full List of 408 DrugCom(s)
55 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
AC220 + Azacitidine DC080LO AC220 FLT3 Gene Mutation Negative [6]
Azacitidine + Dasatinib DC04YOF Dasatinib Acute Myeloid Leukemia [7]
Azacitidine + Vorinostat DC8Z65K Vorinostat Adult Nasal Type Extranodal NK/T-Cell Lymphoma [8]
Azacitidine + Vorinostat DCL4UYT Vorinostat Acute Erythroid Leukemia [9]
Azacitidine + Azacitidine DCVN0FN Azacitidine Ovarian Cancer [10]
Azacitidine + SNS-595 DC87N20 SNS-595 Myelodysplastic Syndromes [11]
Azacitidine + Ponatinib DCKOCWP Ponatinib Leukemia [12]
Azacitidine + CP-868596 DCSEWL4 CP-868596 Acute Myeloid Leukemia [13]
Belinostat + Azacitidine DCNJBEZ Belinostat Accelerated Phase of Disease [14]
Birinapant + Azacitidine DCHXQNE Birinapant Myelodysplastic Syndrome [15]
Bortezomib + Azacitidine DCVI4CO Bortezomib Adult Nasal Type Extranodal NK/T-cell Lymphoma [16]
Bortezomib + Azacitidine DCWTM2A Bortezomib Leukemia [17]
Carboplatin + Azacitidine DCJJ736 Carboplatin Urinary Bladder Neoplasms [18]
Decitabine + Azacitidine DCU2F3I Decitabine Acute Myeloid Leukemia [19]
Duvelisib + Azacitidine DCAKUM1 Duvelisib Non Hodgkin Lymphoma [20]
Enasidenib + Azacitidine DCO5USM Enasidenib Leukemia, Myeloid, Acute [21]
Lenalidomide + Azacitidine DCC5AOW Lenalidomide Leukemia [22]
Lenalidomide + Azacitidine DCTAJLM Lenalidomide Acute Myeloid Leukemia (AML) [23]
MGCD-0103 + Azacitidine DCQAFEO MGCD-0103 Myelodysplastic Syndrome [24]
Midostaurin + Azacitidine DCT8IBJ Midostaurin Untreated Adult Acute Myeloid Leukemia [25]
Mitoxantrone + Azacitidine DC6TUBF Mitoxantrone Adult Acute Megakaryoblastic Leukemia (M7) [26]
Omacetaxine mepesuccinate + Azacitidine DC9KSIW Omacetaxine mepesuccinate High Grade Myelodysplastic Syndromes [27]
Oxaliplatin + Azacitidine DCUEDWU Oxaliplatin Adult Solid Neoplasm [28]
Oxaliplatin + Azacitidine DC01CHR Oxaliplatin Colorectal Cancer [29]
Pacritinib + Azacitidine DCXJ1WS Pacritinib Chronic Myelomonocytic Leukemia [30]
Panobinostat + Azacitidine DCN0JBZ Panobinostat Myelodysplastic Syndromes [31]
PF-04449913 + Azacitidine DCGSXOM PF-04449913 Acute Myeloid Leukemia [32]
Plerixafor + Azacitidine DCXYJYV Plerixafor Myelodysplastic Syndromes [33]
Rigosertib + Azacitidine DC9U5I8 Rigosertib Myelodysplastic Syndrome [34]
Romidepsin + Azacitidine DC7JHI1 Romidepsin Lymphoid Malignancies [35]
Ruxolitinib + Azacitidine DCAW80U Ruxolitinib Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable [36]
Selumetinib + Azacitidine DCAQJZQ Selumetinib Chronic Myeloid Leukemia [37]
TP-0903 + Azacitidine DCHQ124 TP-0903 Acute Myeloid Leukemia [38]
Trametinib + Azacitidine DCVV9AB Trametinib Leukemia, Juvenile Myelomonocytic [39]
Valproic Acid + Azacitidine DCJU0V3 Valproic Acid Acute Myelogenous Leukemia [40]
Venetoclax + Azacitidine DCLNFXB Venetoclax Recurrent Acute Myeloid Leukemia [41]
Venetoclax + Azacitidine DCMRE6O Venetoclax Acute Myeloid Leukemia (AML) [42]
Venetoclax + Azacitidine DC0TMY5 Venetoclax Myelodysplastic Syndromes (MDS) [43]
Venetoclax + Azacitidine DCM504K Venetoclax Acute Myelogenous Leukemia [44]
Azacitidine + Pracinostat DC3B3AG Pracinostat Myelodysplastic Syndromes [45]
Azacitidine + SNS-595 DC4Z2WK SNS-595 Acute Myeloid Leukemia [46]
Azacitidine + Ponatinib DCFIDQS Ponatinib CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE [47]
Azacitidine + Acetylcysteine DCKC44Y Acetylcysteine Thrombocytopenia, Isolated [48]
Azacitidine + Pracinostat DCLV1F2 Pracinostat Myelodysplastic Syndrome [49]
Daunorubicin + Azacitidine DCKWNXK Daunorubicin MDS [50]
Decitabine + Azacitidine DC77UG3 Decitabine Myelodysplastic Syndrome [51]
Enasidenib + Azacitidine DCP3FID Enasidenib Acute Myeloid Leukemia [52]
Fulvestrant + Azacitidine DC339GI Fulvestrant Breast Neoplasms [53]
Tamibarotene + Azacitidine DCQ65TW Tamibarotene Acute Myeloid Leukemia [54]
Azacitidine + Cytarabine DCIOOE9 Cytarabine Relapsed or Refractory Acute Myeloid Leukemia [55]
Azacitidine + Gilteritinib DC2AUA6 Gilteritinib Acute Myeloid Leukemia (AML) [56]
Dexamethasone + Azacitidine DCS22UQ Dexamethasone Relapsed or Refractory Acute Myeloid Leukemia [55]
Ivosidenib + Azacitidine DCDNOQ3 Ivosidenib Newly Diagnosed Acute Myeloid Leukemia (AML) [57]
PF-04449913 + Azacitidine DCAYEPZ PF-04449913 Acute Myeloid Leukemia [58]
Tamibarotene + Azacitidine DCIEAN8 Tamibarotene Myelodysplastic Syndromes [59]
------------------------------------------------------------------------------------
⏷ Show the Full List of 55 DrugCom(s)

References

1 Azacitidine FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6796).
3 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
4 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
5 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
6 ClinicalTrials.gov (NCT01892371) Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
7 ClinicalTrials.gov (NCT05042531) Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia
8 ClinicalTrials.gov (NCT00336063) Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma
9 ClinicalTrials.gov (NCT00392353) Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
10 ClinicalTrials.gov (NCT00842582) Azacitidine With Carboplatin and Paclitaxel for Newly Diagnosed Ovarian Cancer
11 ClinicalTrials.gov (NCT01913951) Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes
12 ClinicalTrials.gov (NCT02829840) Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)
13 ClinicalTrials.gov (NCT02400281) Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients
14 ClinicalTrials.gov (NCT00351975) Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases
15 ClinicalTrials.gov (NCT01828346) Birinapant With 5-azacitidine in MDS Subjects Who Are Nave, Have Relapsed or Are Refractory to 5-azacitidine Therapy
16 ClinicalTrials.gov (NCT01129180) Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
17 ClinicalTrials.gov (NCT00624936) Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes
18 ClinicalTrials.gov (NCT01478685) A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
19 ClinicalTrials.gov (NCT02954653) A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia
20 ClinicalTrials.gov (NCT05065866) Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
21 ClinicalTrials.gov (NCT02677922) A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy
22 ClinicalTrials.gov (NCT00352001) Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes
23 ClinicalTrials.gov (NCT00890929) Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML)
24 ClinicalTrials.gov (NCT02018926) Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
25 ClinicalTrials.gov (NCT01093573) Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia
26 ClinicalTrials.gov (NCT01839240) Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia
27 ClinicalTrials.gov (NCT03564873) Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS
28 ClinicalTrials.gov (NCT01039155) Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy
29 ClinicalTrials.gov (NCT01193517) Azacitidine and CAPOX in Metastatic Colorectal Cancer
30 ClinicalTrials.gov (NCT06159491) Pacritinib in CMML
31 ClinicalTrials.gov (NCT00946647) A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).
32 ClinicalTrials.gov (NCT02038777) A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies
33 ClinicalTrials.gov (NCT01065129) Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS)
34 ClinicalTrials.gov (NCT01926587) Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
35 ClinicalTrials.gov (NCT01998035) Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies
36 ClinicalTrials.gov (NCT01787487) Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm
37 ClinicalTrials.gov (NCT03326310) Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
38 ClinicalTrials.gov (NCT04518345) TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia
39 ClinicalTrials.gov (NCT05849662) A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
40 ClinicalTrials.gov (NCT00382590) Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients
41 ClinicalTrials.gov (NCT04140487) Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
42 ClinicalTrials.gov (NCT05520567) A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia
43 ClinicalTrials.gov (NCT02942290) A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Nave Higher-Risk Myelodysplastic Syndromes (MDS)
44 ClinicalTrials.gov (NCT02203773) Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)
45 ClinicalTrials.gov (NCT03151304) A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes
46 ClinicalTrials.gov (NCT03338348) Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2
47 ClinicalTrials.gov (NCT03895671) PONAZA : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS
48 ClinicalTrials.gov (NCT05126004) AZA Combined With NAC for PIT After HSCT
49 ClinicalTrials.gov (NCT01873703) Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome
50 ClinicalTrials.gov (NCT04061239) Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML
51 ClinicalTrials.gov (NCT01993641) Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
52 ClinicalTrials.gov (NCT03383575) Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
53 ClinicalTrials.gov (NCT02374099) Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant
54 ClinicalTrials.gov (NCT02807558) A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome
55 ClinicalTrials.gov (NCT03765541) Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia
56 ClinicalTrials.gov (NCT02752035) A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy
57 ClinicalTrials.gov (NCT03173248) Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
58 ClinicalTrials.gov (NCT04842604) Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML
59 ClinicalTrials.gov (NCT04797780) SY-1425 Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome. U.S. National Institutes of Health.